Introduction This prospective, single-site, non-randomized, open-label controlled pilot study aims to generate preliminary evidence on the short-term safety and potential immunomodulatory effects of Suvarnaprashana (SP), a traditional Ayurvedic intervention involving daily oral administration of a gold-based formulation (Suvarna Bhasma triturated with honey and ghee). Study Objectives Primary objectives focus on safety (monitoring adverse events, serious adverse events, and biochemical markers) and exploratory immunological changes (white blood cell differentials, immunoglobulins IgA/IgM/IgG, T-cell subsets CD4+/CD8+, cytokine IL-4, and infection incidence). Secondary objectives include monitoring gastrointestinal problems and overall infection episodes via caregiver logs and clinical assessments. Study Methods This prospective, open-label, controlled pilot study in Nepal enrolls healthy children. Children receive Suvarnaprashana or control (no intervention/standard care). Data collected via parental illness diaries, anthropometry, clinical examinations, and questionnaires at baseline and follow-ups assess safety (adverse events) and efficacy (immunity and morbidity). Analysis uses descriptive stats and basic comparisons. Expected Outcomes The pilot study anticipates demonstrating Suvarnaprashana as safe (low adverse events) with preliminary efficacy signals, including fewer illnesses and enhanced immunity in Nepali children versus controls. Results may justify larger trials and guide safe integration of this traditional practice into pediatric healthcare in Nepal.
Age range
2 Years – 5 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants with Adverse Events
Timeframe: 8 weeks
Change in ALT (IU/L)
Timeframe: 8 weeks
Change in AST (IU/L)
Timeframe: 8 weeks
Change in Bilirubin (mg/dL)
Timeframe: 8 weeks
Change in Creatinine (mg/dL)
Timeframe: 8 weeks
Change in Hemoglobin (g/dL)
Timeframe: 8 weeks
Change in WBC Count (10³/μL)
Timeframe: 8 weeks
Change in Platelet Count (10³/μL)
Timeframe: 8 weeks
Change in Serum Gold (μg/L)
Timeframe: 8 weeks
Change in Urine Gold (μg/L)
Timeframe: 8 weeks
Change in IgA (mg/dL)
Timeframe: 8 weeks
Change in IgM (mg/dL)
Timeframe: 8 weeks
Change in IgG (mg/dL)
Timeframe: 8 weeks
Change in CD4+ T Cell Count (cells/μL)
Timeframe: 8 weeks
Change in CD8+ T Cell Count (cells/μL)
Timeframe: 8 weeks
Change in IL-4 (pg/mL)
Timeframe: 8 weeks
Number of Infection Episodes per Participant
Timeframe: 8 weeks